within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ05_Dulaglutide;

model Dulaglutide
  extends Pharmacolibrary.Drugs.ATC.A.A10BJ05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BJ05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dulaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. It improves glycemic control by enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Dulaglutide is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult type 2 diabetic patients, following repeated subcutaneous administration. Parameters reflect pooled values from both sexes across multiple doses. Population PK analysis, mainly in adults aged 18-75, various ethnic groups.</p><h4>References</h4><ol><li><p>Pratley, RE, et al., &amp; Viljoen, A (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <i>The lancet. Diabetes &amp; endocrinology</i> 6(4) 275–286. DOI:<a href=\"https://doi.org/10.1016/S2213-8587(18)30024-X\">10.1016/S2213-8587(18)30024-X</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29397376/\">https://pubmed.ncbi.nlm.nih.gov/29397376</a></p></li><li><p>Bucheit, JD, et al., &amp; Sisson, EM (2020). Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. <i>Diabetes technology &amp; therapeutics</i> 22(1) 10–18. DOI:<a href=\"https://doi.org/10.1089/dia.2019.0185\">10.1089/dia.2019.0185</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31436480/\">https://pubmed.ncbi.nlm.nih.gov/31436480</a></p></li><li><p>Urva, S, et al., &amp; Milicevic, Z (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. <i>Lancet (London, England)</i> 400(10366) 1869–1881. DOI:<a href=\"https://doi.org/10.1016/S0140-6736(22)02033-5\">10.1016/S0140-6736(22)02033-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36354040/\">https://pubmed.ncbi.nlm.nih.gov/36354040</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dulaglutide;
